GlassScriptPhysician profile
Ferdinand C Manlio
NPI 1669444113
$14,680.84
in general payments reported to CMS, 2019-2025
36 companies · $3,174 in 2025
The $3,174 reported for 2025 was more than what 85% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,287 · 2020: $1,097 · 2021: $1,740 · 2022: $2,540 · 2023: $2,106 · 2024: $2,737 · 2025: $3,174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,561 · Education: $456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,560.89 |
| Education | $456.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,075.05 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,532.14 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,529.43 | 2019-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $1,501.08 | 2019-2025 | Tremfya |
| Amgen INC. | $1,291.45 | 2020-2025 | Otezla, Otezla |
| Pfizer INC. | $1,244.92 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $1,062.99 | 2019-2025 | |
| Genzyme Corporation | $880.02 | 2019-2025 | |
| Lilly USA, LLC | $596.16 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $541.50 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $276.82 | 2019-2024 | Cabtreo, Arazlo, Jublia |
| Hill Dermaceuticals, INC. | $221.88 | 2021 | |
| Ucb, INC. | $210.84 | 2021-2024 | Bimzelx, Cimzia |
| Genentech USA, INC. | $205.95 | 2019-2021 | |
| Galderma Laboratories, L.P. | $191.72 | 2022-2025 | Nemluvio, Aklief, Epsolay |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $185.57 | 2021-2025 | Opzelura |
| Biofrontera INC. | $177.70 | 2022-2025 | Ameluz, Xepi, Bf-Rhodoled |
| E.R. Squibb & Sons, L.L.C. | $157.54 | 2022-2025 | Sotyktu |
| Janssen Scientific Affairs, LLC | $124.92 | 2019 | |
| Dermavant Sciences, INC. | $103.80 | 2023 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.46 | 2023-2024 | Spevigo |
| Celgene Corporation | $80.36 | 2019 | |
| Dermira, INC. | $67.00 | 2019-2020 | |
| Leo Pharma INC. | $58.61 | 2019-2024 | Adbry |
| Almirall LLC | $43.12 | 2019-2021 | |
| Organogenesis INC. | $39.98 | 2023-2024 | Puraply |
| Botanix Sb INC | $34.74 | 2025 | Sofdra |
| Dusa Pharmaceuticals, INC. | $23.99 | 2019 | |
| Sanofi-Aventis U.S. LLC | $23.19 | 2020 | |
| Sandoz INC. | $20.53 | 2020 | |
| Nabriva Therapeutics, Plc | $19.86 | 2021 | |
| Encore Dermatology INC. | $17.63 | 2019 | |
| Vyne Pharmaceuticals INC. | $17.01 | 2020 | |
| Verrica Pharmaceuticals INC. | $15.83 | 2024 | Ycanth |
| Sebela Pharmaceuticals INC. | $13.40 | 2020 | |
| Strata Skin Sciences, INC. | $6.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ferdinand Manlio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.